MedPath

A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer

Phase 3
Completed
Conditions
Pancreatic Cancer
Registration Number
NCT00051467
Lead Sponsor
GenVec
Brief Summary

The primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line treatment of unresectable locally advanced pancreatic cancer.

TNFerade™ is a replication deficient adenovirus vector containing the gene for TNF-alpha controlled by a chemoradiation inducible promoter. This allows the expression of TNF-alpha to be greatest in the area receiving radiation. TNF-alpha is a cytokine that has been shown to have potent anti-cancer activities but, due to systemic toxicity, could not be delivered at effective doses. TNFerade™ Biologic is a novel way of selective delivery of TNF-alpha to tumor cells.

TNFerade™ Biologic will be injected during five weekly injection sessions, concomitant with radiation and 5-FU. TNFerade™ Biologic will be administered by direct intratumoral injection using a percutaneous approach (PTA) or endoscopic ultrasound (EUS).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (25)

University of California San Diego Moores Cancer Center

🇺🇸

La Jolla, California, United States

UCLA School of Medicine, Division of Hematology-Oncology

🇺🇸

Los Angeles, California, United States

UC Irvine Medical Center

🇺🇸

Orange, California, United States

University of Colorado Health Science Center Facility

🇺🇸

Denver, Colorado, United States

Georgetown, MedStar Research Institute

🇺🇸

Washington, District of Columbia, United States

H. Lee Moffitt Cancer Center & Research Institute

🇺🇸

Tampa, Florida, United States

Tampa General Hospital

🇺🇸

Tampa, Florida, United States

Winship Cancer Center, Emory University

🇺🇸

Atlanta, Georgia, United States

The Universtiy of Chicago Medical Center

🇺🇸

Chicago, Illinois, United States

St. James Hospital and Health Centers Comprehensive Cancer Institute

🇺🇸

Olympia Fields, Illinois, United States

Scroll for more (15 remaining)
University of California San Diego Moores Cancer Center
🇺🇸La Jolla, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.